NASDAQ:SNGX Soligenix (SNGX) Stock Price, News & Analysis $3.04 +0.04 (+1.33%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Soligenix Stock (NASDAQ:SNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Soligenix alerts:Sign Up Key Stats Today's Range$2.99▼$3.1650-Day Range$1.12▼$4.9652-Week Range$1.09▼$6.23Volume212,426 shsAverage Volume4.34 million shsMarket Capitalization$13.04 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Read More Soligenix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreSNGX MarketRank™: Soligenix scored higher than 43% of companies evaluated by MarketBeat, and ranked 664th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSoligenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoligenix has only been the subject of 1 research reports in the past 90 days.Read more about Soligenix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Soligenix are expected to grow in the coming year, from ($4.65) to ($2.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soligenix is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soligenix is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoligenix has a P/B Ratio of 6.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soligenix's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.40% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 16.73%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSoligenix does not currently pay a dividend.Dividend GrowthSoligenix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.40% of the float of Soligenix has been sold short.Short Interest Ratio / Days to CoverSoligenix has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Soligenix has recently increased by 16.73%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.65 News SentimentSoligenix has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Soligenix this week, compared to 1 article on an average week.Search Interest22 people have searched for SNGX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows4 people have added Soligenix to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Soligenix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Soligenix is held by insiders.Percentage Held by InstitutionsOnly 3.60% of the stock of Soligenix is held by institutions.Read more about Soligenix's insider trading history. Receive SNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNGX Stock News HeadlinesSoligenix Inc. Reports Q2 2025 Earnings LossAugust 22, 2025 | msn.comCompanies Like Soligenix (NASDAQ:SNGX) Could Be Quite RiskyAugust 21, 2025 | finance.yahoo.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.August 28 at 2:00 AM | SmartAsset (Ad)Small Cap Stocks To Follow Today - August 18thAugust 20, 2025 | americanbankingnews.comSoligenix (NASDAQ:SNGX) Cut to Strong Sell at Wall Street ZenAugust 19, 2025 | americanbankingnews.comWhy Is Soligenix Stock Soaring On Monday?August 18, 2025 | benzinga.comSoligenix’s dusquetide granted Orphan Drug Designation in Behcet’s DiseaseAugust 18, 2025 | msn.comSoligenix stock soars after FDA grants orphan drug designationAugust 18, 2025 | za.investing.comSee More Headlines SNGX Stock Analysis - Frequently Asked Questions How have SNGX shares performed this year? Soligenix's stock was trading at $2.69 at the start of the year. Since then, SNGX shares have increased by 11.5% and is now trading at $3.00. How were Soligenix's earnings last quarter? Soligenix Inc. (NASDAQ:SNGX) announced its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $0.03. When did Soligenix's stock split? Soligenix's stock reverse split on Thursday, June 6th 2024.The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Who are Soligenix's major shareholders? Top institutional investors of Soligenix include Connective Capital Management LLC (3.67%). View institutional ownership trends. How do I buy shares of Soligenix? Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Soligenix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX). Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNGX CIK812796 Webwww.soligenix.com Phone(609) 538-8200Fax609-452-6467Employees20Year Founded1987Price Target and Rating Average Price Target for Soligenix$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+100.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.27 million Net MarginsN/A Pretax Margin-499,900.00% Return on Equity-274.76% Return on Assets-129.20% Debt Debt-to-Equity RatioN/A Current Ratio1.47 Quick Ratio1.47 Sales & Book Value Annual Sales$120 thousand Price / Sales107.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / Book6.98Miscellaneous Outstanding Shares4,290,000Free Float4,155,000Market Cap$12.87 million OptionableNot Optionable Beta1.95 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:SNGX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.